Caplin Point Laboratories Ltd reported a consolidated net profit of ₹145.28 crore for the quarter ended March 31, 2025, marking a 19.8% increase compared to ₹121.23 crore in the same quarter last year. The net profit attributable to equity shareholders stood at ₹142.57 crore, up 17.5% from ₹121.59 crore in Q4 FY24.
The company’s total income rose 11.2% year-on-year to ₹528.19 crore in Q4 FY25 from ₹470.51 crore in the corresponding period last year. Revenue from operations stood at ₹502.45 crore, an increase of 10.9% from ₹453.22 crore in Q4 FY24.
EBITDA performance improves
Caplin Point’s earnings before interest, tax, depreciation and amortisation (EBITDA) for Q4 FY25 came in at ₹194 crore, compared to ₹162 crore in Q4 FY24, reflecting a growth of nearly 19.8%. The EBITDA margin improved to 36.7% from 34.5% in the year-ago period, indicating enhanced operating efficiency.
Expenses for the quarter rose to ₹351.60 crore, up 8.3% compared to ₹324.54 crore a year earlier. Among key expense heads, purchase of traded goods nearly doubled YoY to ₹138.77 crore from ₹62.65 crore, while employee benefit expenses grew to ₹46.51 crore from ₹36.77 crore.
Profit before tax for the quarter came in at ₹176.67 crore, up 21% compared to ₹146.03 crore in Q4 FY24. Tax expenses rose to ₹31.39 crore from ₹24.80 crore in the same quarter last year.
For the full year FY25, the company reported a net profit of ₹541.09 crore, a 17.2% rise over ₹461.42 crore in FY24. Revenue from operations stood at ₹1,937.47 crore for the year, up 14.3% from ₹1,694.10 crore last year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
